Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 diabetes patients in the U.S. The company said in March that it was cutting the price of its drug Wegovy to $499. The two drugs are similar, with Wegovy prescribed primarily for weight loss for obese patients. Ozempic is prescribed to patients with type 2 diabetes. Eli Lilly announced earlier this year that it would expand the supply and cut the costs of its weight-loss drug Zepbound, again ...

Jakarta, Indonesia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- NusaTrip Incorporated (“NusaTrip,” “NUTR” or the “Company”), a travel ecosystem with geographical specialization in Southeast Asia and Asia-Pacific, today announced the closing of its previously announced initial public offering of an aggregate 3,750,000 shares of Common Stock (“the Offering”) at a price of $4.00 per share (“the Offering Price”) to the public, for a total of $15.0 million of gross proceeds to the Company, before deducting underwriting di ...

Opera Limited OPRA will release financial results for the second quarter before the opening bell on Tuesday, Aug. 19.Analysts expect the Oslo, Norway-based company to report quarterly earnings at 26 cents per share, down from 44 cents per share in the year-ago period. Opera projects to report quarterly revenue at $137.44 million, compared to $109.73 million a year earlier, according to data from Benzinga Pro.On April 28, Opera announced better-than-expected first-quarter financial results and raised its FY2 ...

On August 18, 2025, a reconvened meeting of creditors (hereinafter – the Meeting) of the AUGA group, AB under restructuring (legal entity code 126264360, registered office address: Konstitucijos pr. 21C, Vilnius; hereinafter – the Company) took place. Over 73% of all creditors participated in the meeting, therefore a quorum was reached. The absolute majority of votes of all participating creditors - only 5 per cent of all participating creditors voted against - approved the draft restructuring plan of AUGA ...

On its face, Kenvue (NYSE: KVUE ) admittedly doesn't look like much right now. Organic revenue for the consumer health giant fell 2.7% year-over-year in the first half of the year. Guidance suggests minimal, if any, improvement in the secondI've been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a small, tech-fo ...

Core Viewpoint - ServiceNow's stock has declined 18.2% year to date, attributed to macroeconomic pressures and tightening budgets, while the broader Computer & Technology sector has appreciated 13.8% during the same period [1][2]. Group 1: Financial Performance - ServiceNow's subscription revenue rose 22.5% year over year to $3.11 billion in Q2 2025, driven by its AI-driven platform [5][8]. - The Zacks Consensus Estimate for Q3 2025 earnings is $4.22 per share, indicating a 13.44% increase over 2024, with revenues expected to grow 19.88% to $3.35 billion [12]. Group 2: AI Strategy and Partnerships - ServiceNow has developed a broad AI ecosystem anchored by its AI Control Tower, enhancing its enterprise AI capabilities [5]. - The partnership with NVIDIA on the Nemotron large language model expands reasoning capabilities and has resulted in significant deals, including a $20 million Now Assist agreement [6][7]. - Acquisitions like data.world and Logik.ai bolster ServiceNow's data governance and configure-price-quote capabilities, respectively, positioning the company as a central platform for enterprise AI operations [7][9]. Group 3: Market Dynamics and Competition - ServiceNow is facing tighter budgets and longer procurement cycles, which are slowing deal closures and creating execution risks [13][15]. - The federal segment is under pressure due to budget constraints, impacting near-term growth visibility despite new customer additions [14]. - Competition is intensifying, particularly from Salesforce and Microsoft, necessitating ServiceNow to demonstrate differentiation in its AI offerings [15][18]. Group 4: Customer Metrics - ServiceNow ended Q2 with 528 customers generating over $5 million in annual contract value, with a 98% renewal rate indicating strong customer satisfaction [11].

Group 1 - TKO Group Holdings, Inc. (TOWN) is experiencing significant activity in the options market, particularly with the Oct 17, 2025 $230.00 Put showing high implied volatility, indicating potential for a major price movement [1] - Implied volatility reflects market expectations for future stock movement, suggesting that investors anticipate a significant event that could lead to a rally or sell-off [2] - TKO Group Holdings currently holds a Zacks Rank 3 (Hold) in the Film and Television Production and Distribution Industry, which is in the bottom 14% of the Zacks Industry Rank [3] Group 2 - Over the past 60 days, two analysts have raised their earnings estimates for TKO Group Holdings for the current quarter, while one has lowered theirs, resulting in a consensus estimate increase from 56 cents to 74 cents per share [3] - The high implied volatility may indicate a developing trading opportunity, as seasoned options traders often seek to sell premium on such options to capture decay, hoping the stock does not move as much as expected by expiration [4]

Group 1 - Poland is experiencing strong economic performance and is one of the fastest growing countries in Europe [1] - The iShares MSCI Poland ETF (NYSEARCA: EPOL) is the only ETF focused on Poland available in the market [1]

Soligenix, Inc. SNGX stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet’s Disease.Follow SNGX stock’s rise today here.The update follows the review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet’s Disease.The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for rare diseases and disord ...

RBC Capital's Christopher Dendrinos upgraded Sunrun RUN to Outperform with a $16 price target. There is clearer long-term growth visibility after the recent U.S. Treasury guidance eased regulatory uncertainty, he explained.Dendrinos noted that the updated framework strengthens demand, supports cash generation. It also positions Sunrun to gain market share as policy shifts favor its third-party ownership (TPO) model.Treasury clarification on "commence construction" rules removes much of the prior uncertainty ...